Review of Andexanet alfa and implications for global health
Direct oral anticoagulants continue to be frequently utilized in various healthcare settings. As such, reversal agents for these medications are being investigated and are making their way into the market. Andexanet alfa is a reversal agent that was manufactured by Portola Pharmaceuticals and FDA-approved in May of 2018 for reversal of rivaroxaban and apixaban. This…